![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, March 06, 2018 3:07:55 PM
They got fast track in 2003, orphan drug status in 2014, initial phase 3 results in May of 2016, breakthrough designation May 2017, priority review, June 2017, and approval today.
But miraculously we are going to fly to approval. No matter what, we have a long way to go. So before you throw out clueless, research what you point out. Or do the facts I present, support your argument?
And besides, that's why they haven't updated clinical trials site since Jan of this year. Where's the 40 sites coming.
Or why are they offering rsu' sin stead of the more palatable options? If something big we're to be coming, I'm sure employees would be motivated by options alone. But ya, any day now.
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM